Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Oncology

FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines

Diana Ernst, RPh

January 7, 2021

Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.

General Oncology

Moderna’s COVID-19 Vaccine Gets EUA; Shipping Begins

Diana Ernst, RPh

December 23, 2020

The EUA was based on data from the placebo-controlled COVE study that investigated the efficacy and safety of mRNA-1273 in more than 30,000 adults aged 18 years and older.

General Oncology

FDA Panel Recommends EUA for Moderna’s COVID-19 Vaccine

Diana Ernst, RPh

December 22, 2020

The EUA recommendation was based on data from the placebo-controlled COVE study that investigated the efficacy and safety of mRNA-1273 in more than 30,000 adults aged 18 years and older.

General Oncology

Pfizer, BioNTech COVID-19 Vaccine Gets EUA; First Doses Shipped

Diana Ernst, RPh

December 15, 2020

The allocation and distribution of vaccine is being managed by the Department of Defense, in partnership with agencies within the Department of Health and Human Services.

General Oncology

ACIP: COVID-19 Vaccine Should Be Offered to HCPs, LTC Residents First

Diana Ernst, RPh

December 4, 2020

The recommendation was made based on the number of confirmed COVID-19 cases among these 2 groups, as well as ethical and scientific considerations.

General Oncology

Final Analysis Reveals COVID-19 Vaccine Candidate BNT162b2 95% Effective

Diana Ernst, RPh

November 20, 2020

The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.

General Oncology

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective

Diana Ernst, RPh

November 17, 2020

The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.